ArticleAcute medicine & surgery2018
Immunoadjuvant therapy in sepsis: novel strategies for immunosuppressive sepsis coming down the pike.
Article in Acute medicine & surgery, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 1 synthesis or guideline pooled it, 38 citations in OpenAlex.
- Anti-PD-L1 Therapy Does Not Improve Survival in a Murine Model of Lethal Staphylococcus aureus Pneumonia.The Journal of infectious diseases · 2021Pooled it
- Pharmacokinetics, Pharmacodynamics, and Safety of Nivolumab in Patients With Sepsis-Induced Immunosuppression: A Multicenter, Open-Label Phase 1/2 Study.Shock (Augusta, Ga.) · 2020Trial
- Sepsis-related immunosuppression: a comprehensive review of current research breakthroughs.Critical care (London, England) · 2026Review
- Investigation of the effects of nicotinamide mononucleotide on kidney damage in rats with cecal ligation and perforation sepsis model.Acta cirurgica brasileira · 2026Article
- Immunoadjuvant therapy in the regulation of cell death in sepsis: recent advances and future directions.Frontiers in immunology · 2024Review
- Ex Vivo Endotoxin Stimulation of Blood for Predicting Survival in Patients With Sepsis: A Systematic Review.CHEST critical care · 2023Article
- Comparison of whole blood cytokine immunoassays for rapid, functional immune phenotyping in critically ill patients with sepsis.Intensive care medicine experimental · 2023Article
- The deacetylation of Akt by SIRT1 inhibits inflammation in macrophages and protects against sepsis.Experimental biology and medicine (Maywood, N.J.) · 2023Article
- Potential therapeutic effect of3 Biotech · 2023Article
- Lymphocyte HVEM/BTLA co-expression after critical illness demonstrates severity indiscriminate upregulation, impacting critical illness-induced immunosuppression.Frontiers in medicine · 2023Article
- Changes in Early T-Cell Subsets and Their Impact on Prognosis in Patients with Sepsis: A Single-Center Retrospective Study.International journal of clinical practice · 2023Article
- Point-of-critical-care diagnostics for sepsis enabled by multiplexed micro and nanosensing technologies.Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology · 2021Review
- Anti-TIGIT differentially affects sepsis survival in immunologically experienced versus previously naive hosts.JCI insight · 2021Article
- Sepsis-Pathophysiology and Therapeutic Concepts.Frontiers in medicine · 2021Review
- Peripheral blood inflammatory markers in predicting prognosis in patients with COVID-19. Some differences with influenza A.Journal of clinical laboratory analysis · 2021Article
- CD8International journal of medical sciences · 2021Article
- Design of a Multiplexed Analyte Biosensor using Digital Barcoded Particles and Impedance Spectroscopy.Scientific reports · 2020Article
- Review
- The Pathogenesis of Sepsis and Potential Therapeutic Targets.International journal of molecular sciences · 2019Review
- Pathological alteration and therapeutic implications of sepsis-induced immune cell apoptosis.Cell death & disease · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 2 countries.
Funding
Abstract
Recent efforts have focused on immunoadjuvant therapies for sepsis. The host inflammatory response consequent to initial exposure to pathogens is often followed by anti-inflammatory forces, resulting in increased morbidity and mortality in such critically ill patients. In the subacute stage of sepsis, apoptosis (type I programmed cell death) and subsequently autophagy (type II programmed cell death) have been attracting recent research interest. Although many patients may die during the initial cytokine storm, those who survive this phase might acquire defining characteristics of profound immunosuppression, including failure to clear the primary infection, development of secondary opportunistic infections, and reactivation of latent viruses. Both types of cell death are currently thought to be associated with this subacute immunosuppressive phase of sepsis, and acceleration of autophagy might alleviate immunosuppression through regulation of apoptosis of key immune effector cells. Programmed cell death 1 (PD-1) and its corresponding ligand play a major pathological role in immunosuppression not only in cancer but also in sepsis. Positive costimulatory pathways in T cells, such as CD28 signaling, permit the effector T cell to expand, persist, and effectively clear antigen. However, PD-1 is a negative costimulatory pathway on T cells that broadly enhances immunosuppressive signals across the innate and adaptive immune system. To counter this immunosuppression in sepsis, checkpoint blockade has garnered attention in an area of clinical research. In this review, we introduce some approaches of immunotherapy using anti-PD-1 antibody in infectious diseases and share our future perspectives.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.